Recruiting
Phase 2

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Sponsor:

Novartis Pharmaceuticals

Code:

NCT03040973

Conditions

Advanced Solid Tumors Which Are cMET-dependent

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Capmatinib

Nazartinib

Gefitinib

Osimertinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information